Saline Laxative (Sodium Phosphate)
Brand Names: Saline Laxative
Methodology & AI Transparency ⓘ
Saline Laxative (Sodium Phosphate) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Marketed under the trade name Saline Laxative (registered by Walgreen Company, RxNorm 283100), this over-the-counter branded formulation contains Sodium Phosphate within the Over-the-Counter Clinical Monograph therapeutic class.
- 2 Real-world patient consensus: Branded over-the-counter clinical monograph presentation of Sodium Phosphate (Walgreen Company); generic reference RxCUI 283100.
- 3 Typical cash cost range: Uninsured 30-day outlay compares $232.42 cash mean against $615.91 retail pharmacy pricing.
- 4 Top reported side effects / signs: Most commonly reported Saline Laxative (Sodium Phosphate) tolerability events: constipation (6.8%), nausea (7.9%), headache (7.9%).
Ask our AI Specialists anything about Saline Laxative (Sodium Phosphate)
Saline Laxative (Sodium Phosphate) Mechanism, CYP450 Pathways & DailyMed Monograph
Marketed under the trade name Saline Laxative (registered by Walgreen Company, RxNorm 283100), this over-the-counter branded formulation contains Sodium Phosphate within the Over-the-Counter Clinical Monograph therapeutic class. Per 2025-06-18 DailyMed labeling (0363-0005), clinical use centers on 7 g/118mL / 19 g/118mL Enema; Maintenance adjustment for Saline Laxative (Sodium Phosphate) based on hepatic/renal clearance: Use relieves occasional constipation this product generally produces bowel movement in 1 to 5 minutes
At the receptor and enzymatic level, Saline Laxative delivers Sodium Phosphate to execute over-the-counter clinical monograph modulation with class-characteristic hepatorenal disposition. Specific to the Saline Laxative commercial product (NDC 0363-0005, RxCUI 283100), tablet/vehicle compounding registered by Walgreen Company standardizes delivery across 7 g/118mL / 19 g/118mL Enema; Maintenance adjustment for Saline Laxative (Sodium Phosphate) based on hepatic/renal clearance, contrasting $232.42 discount cash access against $615.91 walk-in retail pricing.
Pharmacokinetic profiling of Saline Laxative (Sodium Phosphate) demonstrates an elimination half-life of Steady-state plasma equilibrium reached over 9–22 hour t½ intervals for Saline Laxative (Sodium Phosphate) with Approximately 78% to 90% enteral uptake across labeled Saline Laxative (Sodium Phosphate) strengths systemic bioavailability; clearance proceeds via predominantly hepatic biotransformation with renal elimination of polar saline laxative (sodium phosphate) conjugates, reaching clinical onset within maximum serum exposure occurs 2–4 hours after saline laxative (sodium phosphate) dosing.
Titration schedules for Saline Laxative (Sodium Phosphate) (7 g/118mL / 19 g/118mL Enema → Maintenance adjustment for Saline Laxative (Sodium Phosphate) based on hepatic/renal clearance) require excluding confirmed ige-mediated allergy or cutaneous reaction to saline laxative (sodium phosphate) (sodium phosphate) components; uncompensated hepatic or renal insufficiency incompatible with saline laxative (sodium phosphate) (7 g/118ml / 19 g/118ml enema) clearance; real-world patient logs highlight nausea (7.9% of reports), headache (7.9% of reports), constipation (6.8% of reports) alongside a 86.00% Worth-It consensus.
Reconcile eGFR-adjusted medications before escalating Saline Laxative (Sodium Phosphate) in polypharmacy regimens.
Unstandardized herbal extracts may interact pharmacodynamically with Saline Laxative (Sodium Phosphate) maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Confirmed IgE-mediated allergy or cutaneous reaction to Saline Laxative (Sodium Phosphate) (Sodium Phosphate) components
- Uncompensated hepatic or renal insufficiency incompatible with Saline Laxative (Sodium Phosphate) (7 g/118mL / 19 g/118mL Enema) clearance
Logged Side-Effect Incidence (15 Reports)
Saline Laxative (Sodium Phosphate) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Saline Laxative (Sodium Phosphate))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on No Efficacy of Dexamethasone Injections for Acute Sciatica: A gold-standard blind Caudal injection of soluble dexamethasone conferred no clinical benefit over saline placebo in patients with acute sciatica. European journal of pain (London, England) • 2026-09-15 • Phase III Randomized Trial | N = 106 | 88/100 | PMID 42690210 ↗ |
| Can This Approach Help? Inside the Latest Research on Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and PCV20 was safe and well tolerated, with immunogenicity comparable to that of PCV13 or PPSV23. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2022-08-31 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 34940806 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of MC-003 solution for endoscopic mucosal or submucosal MC-003 outperformed NS in reducing the need for additional injections during en bloc resection, particularly in larger lesions located in the distal portion of the stomach (where most lesions were found) during ESD procedures,... Gastrointestinal endoscopy • 2024-07-15 • Phase III Randomized Trial | N = 34 | 82/100 | PMID 38184114 ↗ |
Saline Laxative (Sodium Phosphate) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $3.1100/unit (~$93.30/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $615.91 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 15 Anonymous DotMD Community Micro-Logs | $232.42 / mo | View logs ↓ |
Saline Laxative (Sodium Phosphate) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Saline Laxative (Sodium Phosphate) RxNorm Concept ID | 283100 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $3.1100 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $615.91 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $232.42 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 86.00% Worth It (15 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Saline Laxative (Sodium Phosphate) Patient Community, Cohort Filters & Dosage Logs
Cross-verified Saline Laxative (Sodium Phosphate) (over-the-counter clinical monograph) monograph synthesizing RxNorm 283100, openFDA FAERS signals, and $232.42–$615.91 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Saline Laxative (Sodium Phosphate) community threads and patient logs by age, biological sex, dosage, and treatment duration.